When Dr.Matthew J. Baker saw how late-stage cancer diagnoses devastated families—simply because early detection was too late, too costly, or too complicated—he set out to rewrite the rules.
Not with painful biopsies or multi-week waits.
"But with light, data, and a single drop of blood".
That mission became Dxcover, a University of Strathclyde spin-out pioneering early cancer detection using a revolutionary platform: PANAROMIC™. Developed by Dr. Baker’s team, PANAROMIC™ analyses patient samples through infraredspectroscopy, decoding the tiniest molecular signals of cancer—beforesymptoms appear.
✅Onetest. One day. One small blood sample. Nosurgery. No radiation. No delay.
With just 9μL of blood, Dxcover’s AI-powered spectroscopy reads the full biochemical finger print—proteins, lipids, metabolites—and delivers results in under 24 hours.
How itworks:
🧪Patient → 9μL blood → AI Algorithm → Disease Prediction
🕐All under 24 hours.
🌍Validated across 10+ cancer types including brain, ovarian, colorectal, and pancreatic.
Butwith every innovation, come obstacles. Convincing the world that a droplet of blood could reveal cancer took bold validation, regulatory rigor, and scientific grit. So, they proved all their claims to be true with valid evidence:
📈 Screened Over 9,000 patients
🧬Generated 250,000+ spectral profiles
🏥PANAROMIC™ showed 93% detection at Stage I, and 96% accuracy in brain tumors including 100% glioblastoma detection in earlier trials.
Dxcover’s colorectal, brain, and lung cancer tests are now being validated in globalmulti-center clinical trials—including the EMBRACE, CREATE2,and SPIRALS studies.
TESTIMONIALS
“Dxcovercombines deep technical innovation with machine learning to radically change
the diagnostic landscape.”
—Andrew McNeill, Eos Advisory
“Dxcover’sblood test has the potential to improve the cancer journey by speeding up
diagnosis and helping clinicians make faster decisions.”
—Felix Litzkow, Macmillan Cancer Support
🏅 Winner, First Prize – ESMO 2023 for earlycancer detection
🏥Screening in UK, Europe, USA with patients across 10+ countries
🔬Clinical trials with over 4,700 patients underway
🔗Partnered with top cancer charities, pharma firms, and hospital networks
Total funding raised: £21M+ ($21.4M)
- £7.5M Series A (2023) led by Eos Advisory, joined by Mercia, Scottish Enterprise, SIS Ventures, Norcliffe Capital, Thairm Bio, and the University of Strathclyde
- €2.5M European Innovation Council grant for brain cancer test development
- $6.2M follow-on (2025) backed by Macmillan Cancer Support, Investment Fund for Scotland, and existing allies
Dxcover isn’t just building a better test—it’s building a global platform for fast, affordable, and scalable early detection. The team continues to evolve PANAROMIC™ across cancer types, biospecimens, instruments, and clinical settings—pushing the frontiers of predictive diagnostics.
Because when it comes to cancer, time is the difference between fear and a future.
And Dxcover? They’re giving the world a head start. One patient at a time. One partner at a time. Dont do it alone, build an ecosystem of partners.
